Risk of ovarian cancer according to use of antidepressants, phenothiazines, and benzodiazepines (United States)

P. F. Coogan, L. Rosenberg, J. R. Palmer, Brian Strom, P. D. Stolley, A. G. Zauber, S. Shapiro

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Objectives: An association of increased risk of ovarian cancer with use of antidepressants or benzodiazepine tranquilizers has been reported from a case-control study. We assessed the association between ovarian cancer risk and the use of tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), phenothiazine antipsychotics, and benzodiazepines, in data from the Case-Control Surveillance Study. Methods: From 1976 through 1998, data were collected from hospital patients in Boston, New York, Philadelphia, and Baltimore based on demographic factors, reproductive and medical history, and medication use. In the present analyses, cases of epithelial ovarian cancer (n = 748) were compared with cancer controls (n = 1496) and noncancer controls admitted for trauma and acute infection (n = 1496). We estimated Mantel-Haenszel odds ratios adjusted for age, study center, and year of interview. Results: Odds ratios for regular use (at least 4 days/week for at least 1 month) were compatible with 1.0 for every drug class. For tricyclics and benzodiazepines the upper 95% confidence limits were less than 1.6. For phenothiazines the upper limit was 2.6 with cancer controls and 1.4 with noncancer controls. Only five cases used SSRIs, yielding unstable results. Odds ratios were not increased among women who had used any drug class for at least 5 years, nor among women who had first used them 10 or more years previously. Conclusions: These data do not support an association between regular use of any of the drugs under study with ovarian cancer risk.

Original languageEnglish (US)
Pages (from-to)839-845
Number of pages7
JournalCancer Causes and Control
Volume11
Issue number9
DOIs
StatePublished - Jan 1 2000
Externally publishedYes

Fingerprint

Phenothiazines
Benzodiazepines
Ovarian Neoplasms
Antidepressive Agents
Odds Ratio
Serotonin Uptake Inhibitors
Case-Control Studies
Pharmaceutical Preparations
Reproductive History
Baltimore
Tricyclic Antidepressive Agents
Antipsychotic Agents
Neoplasms
Demography
Interviews
Wounds and Injuries
Infection

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Coogan, P. F. ; Rosenberg, L. ; Palmer, J. R. ; Strom, Brian ; Stolley, P. D. ; Zauber, A. G. ; Shapiro, S. / Risk of ovarian cancer according to use of antidepressants, phenothiazines, and benzodiazepines (United States). In: Cancer Causes and Control. 2000 ; Vol. 11, No. 9. pp. 839-845.
@article{3cdab3eab12b4cdf8cbdea84dc17e3a5,
title = "Risk of ovarian cancer according to use of antidepressants, phenothiazines, and benzodiazepines (United States)",
abstract = "Objectives: An association of increased risk of ovarian cancer with use of antidepressants or benzodiazepine tranquilizers has been reported from a case-control study. We assessed the association between ovarian cancer risk and the use of tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), phenothiazine antipsychotics, and benzodiazepines, in data from the Case-Control Surveillance Study. Methods: From 1976 through 1998, data were collected from hospital patients in Boston, New York, Philadelphia, and Baltimore based on demographic factors, reproductive and medical history, and medication use. In the present analyses, cases of epithelial ovarian cancer (n = 748) were compared with cancer controls (n = 1496) and noncancer controls admitted for trauma and acute infection (n = 1496). We estimated Mantel-Haenszel odds ratios adjusted for age, study center, and year of interview. Results: Odds ratios for regular use (at least 4 days/week for at least 1 month) were compatible with 1.0 for every drug class. For tricyclics and benzodiazepines the upper 95{\%} confidence limits were less than 1.6. For phenothiazines the upper limit was 2.6 with cancer controls and 1.4 with noncancer controls. Only five cases used SSRIs, yielding unstable results. Odds ratios were not increased among women who had used any drug class for at least 5 years, nor among women who had first used them 10 or more years previously. Conclusions: These data do not support an association between regular use of any of the drugs under study with ovarian cancer risk.",
author = "Coogan, {P. F.} and L. Rosenberg and Palmer, {J. R.} and Brian Strom and Stolley, {P. D.} and Zauber, {A. G.} and S. Shapiro",
year = "2000",
month = "1",
day = "1",
doi = "https://doi.org/10.1023/A:1008982417022",
language = "English (US)",
volume = "11",
pages = "839--845",
journal = "Cancer Causes and Control",
issn = "0957-5243",
publisher = "Springer Netherlands",
number = "9",

}

Risk of ovarian cancer according to use of antidepressants, phenothiazines, and benzodiazepines (United States). / Coogan, P. F.; Rosenberg, L.; Palmer, J. R.; Strom, Brian; Stolley, P. D.; Zauber, A. G.; Shapiro, S.

In: Cancer Causes and Control, Vol. 11, No. 9, 01.01.2000, p. 839-845.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Risk of ovarian cancer according to use of antidepressants, phenothiazines, and benzodiazepines (United States)

AU - Coogan, P. F.

AU - Rosenberg, L.

AU - Palmer, J. R.

AU - Strom, Brian

AU - Stolley, P. D.

AU - Zauber, A. G.

AU - Shapiro, S.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Objectives: An association of increased risk of ovarian cancer with use of antidepressants or benzodiazepine tranquilizers has been reported from a case-control study. We assessed the association between ovarian cancer risk and the use of tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), phenothiazine antipsychotics, and benzodiazepines, in data from the Case-Control Surveillance Study. Methods: From 1976 through 1998, data were collected from hospital patients in Boston, New York, Philadelphia, and Baltimore based on demographic factors, reproductive and medical history, and medication use. In the present analyses, cases of epithelial ovarian cancer (n = 748) were compared with cancer controls (n = 1496) and noncancer controls admitted for trauma and acute infection (n = 1496). We estimated Mantel-Haenszel odds ratios adjusted for age, study center, and year of interview. Results: Odds ratios for regular use (at least 4 days/week for at least 1 month) were compatible with 1.0 for every drug class. For tricyclics and benzodiazepines the upper 95% confidence limits were less than 1.6. For phenothiazines the upper limit was 2.6 with cancer controls and 1.4 with noncancer controls. Only five cases used SSRIs, yielding unstable results. Odds ratios were not increased among women who had used any drug class for at least 5 years, nor among women who had first used them 10 or more years previously. Conclusions: These data do not support an association between regular use of any of the drugs under study with ovarian cancer risk.

AB - Objectives: An association of increased risk of ovarian cancer with use of antidepressants or benzodiazepine tranquilizers has been reported from a case-control study. We assessed the association between ovarian cancer risk and the use of tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), phenothiazine antipsychotics, and benzodiazepines, in data from the Case-Control Surveillance Study. Methods: From 1976 through 1998, data were collected from hospital patients in Boston, New York, Philadelphia, and Baltimore based on demographic factors, reproductive and medical history, and medication use. In the present analyses, cases of epithelial ovarian cancer (n = 748) were compared with cancer controls (n = 1496) and noncancer controls admitted for trauma and acute infection (n = 1496). We estimated Mantel-Haenszel odds ratios adjusted for age, study center, and year of interview. Results: Odds ratios for regular use (at least 4 days/week for at least 1 month) were compatible with 1.0 for every drug class. For tricyclics and benzodiazepines the upper 95% confidence limits were less than 1.6. For phenothiazines the upper limit was 2.6 with cancer controls and 1.4 with noncancer controls. Only five cases used SSRIs, yielding unstable results. Odds ratios were not increased among women who had used any drug class for at least 5 years, nor among women who had first used them 10 or more years previously. Conclusions: These data do not support an association between regular use of any of the drugs under study with ovarian cancer risk.

UR - http://www.scopus.com/inward/record.url?scp=0033785802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033785802&partnerID=8YFLogxK

U2 - https://doi.org/10.1023/A:1008982417022

DO - https://doi.org/10.1023/A:1008982417022

M3 - Article

VL - 11

SP - 839

EP - 845

JO - Cancer Causes and Control

JF - Cancer Causes and Control

SN - 0957-5243

IS - 9

ER -